Hedging against Antiviral Resistance during the Next Influenza Pandemic Using Small Stockpiles of an Alternative Chemotherapy

Mathematically simulating an influenza pandemic, Joseph Wu and colleagues predict that using a secondary antiviral drug early in local epidemics would reduce global emergence of resistance to the primary stockpiled drug.

[1]  Alessandro Vespignani,et al.  Modeling the Worldwide Spread of Pandemic Influenza: Baseline Case and Containment Interventions , 2007, PLoS medicine.

[2]  B. Lina,et al.  Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. , 2008, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[3]  Susan Mallett,et al.  A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals. , 2003, The Journal of antimicrobial chemotherapy.

[4]  Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. , 2009, Emerging infectious diseases.

[5]  D. Cummings,et al.  Strategies for mitigating an influenza pandemic , 2006, Nature.

[6]  R. Webster,et al.  Oseltamivir-Ribavirin Combination Therapy for Highly Pathogenic H5N1 Influenza Virus Infection in Mice , 2007, Antimicrobial Agents and Chemotherapy.

[7]  Larisa V. Gubareva,et al.  Surveillance for Neuraminidase Inhibitor Resistance among Human Influenza A and B Viruses Circulating Worldwide from 2004 to 2008 , 2008, Antimicrobial Agents and Chemotherapy.

[8]  A S Perelson,et al.  Emergence of drug resistance during an influenza epidemic: insights from a mathematical model. , 1998, The Journal of infectious diseases.

[9]  Phillip Andrew Reece,et al.  Neuraminidase inhibitor resistance in influenza viruses , 2007, Journal of medical virology.

[10]  C. Fraser,et al.  Reducing the impact of the next influenza pandemic using household-based public health interventions. , 2006, Hong Kong medical journal = Xianggang yi xue za zhi.

[11]  S. Kashiwagi,et al.  A comparison of the effectiveness of zanamivir and oseltamivir for the treatment of influenza A and B. , 2008, The Journal of infection.

[12]  F. Hayden,et al.  Enhancement of activity against influenza viruses by combinations of antiviral agents , 1980, Antimicrobial Agents and Chemotherapy.

[13]  R. Webster,et al.  Amantadine-Oseltamivir Combination therapy for H5N1 Influenza Virus Infection in Mice , 2006, Antiviral therapy.

[14]  Janet Daly,et al.  Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro. , 2006, The Journal of antimicrobial chemotherapy.

[15]  S. Kashiwagi,et al.  Zanamivir treatment is equally effective for both influenza A and influenza B. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  F. Hayden,et al.  Oral LY217896 for prevention of experimental influenza A virus infection and illness in humans , 1994, Antimicrobial Agents and Chemotherapy.

[17]  Update: influenza activity--United States. , 1986, MMWR. Morbidity and mortality weekly report.

[18]  Ping Yan,et al.  Emergence of drug resistance: implications for antiviral control of pandemic influenza , 2007, Proceedings of the Royal Society B: Biological Sciences.

[19]  J. Robins,et al.  Transmissibility of 1918 pandemic influenza , 2004, Nature.

[20]  A. Moscona,et al.  Global transmission of oseltamivir-resistant influenza. , 2009, The New England journal of medicine.

[21]  M Elizabeth Halloran,et al.  Design and evaluation of prophylactic interventions using infectious disease incidence data from close contact groups , 2006, Journal of the Royal Statistical Society. Series C, Applied statistics.

[22]  J. van de Kassteele,et al.  Oseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007–08 Season , 2009, Emerging infectious diseases.

[23]  F. Hayden,et al.  Safety and Efficacy of Nebulized Zanamivir in Hospitalized Patients with Serious Influenza , 2002, Antiviral therapy.

[24]  C. Macken,et al.  Mitigation strategies for pandemic influenza in the United States. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[25]  C. Fraser,et al.  Factors that make an infectious disease outbreak controllable. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Cécile Viboud,et al.  Risk factors of influenza transmission in households. , 2004, The British journal of general practice : the journal of the Royal College of General Practitioners.

[27]  F. Hayden,et al.  John F. Enders lecture 2006: antivirals for influenza. , 2007, The Journal of infectious diseases.

[28]  Lynnette Brammer,et al.  Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. , 2009, JAMA.

[29]  Alan J. Hay,et al.  Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants , 2008, Nature.

[30]  D. Cummings,et al.  Strategies for containing an emerging influenza pandemic in Southeast Asia , 2005, Nature.

[31]  B. Levin,et al.  Antiviral Resistance and the Control of Pandemic Influenza , 2007, PLoS medicine.

[32]  Update: influenza activity--United States, September 30, 2007-February 9, 2008. , 2008, MMWR. Morbidity and mortality weekly report.

[33]  Sebastian Bonhoeffer,et al.  This PDF file includes: SOM Text , 2022 .

[34]  J. Oxford,et al.  The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. , 2002, Antiviral research.

[35]  A. Monto,et al.  Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. , 2004, The Journal of infectious diseases.

[36]  R. Webster,et al.  Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. , 2006, Antiviral research.

[37]  Mark A. Miller,et al.  Synchrony, Waves, and Spatial Hierarchies in the Spread of Influenza , 2006, Science.

[38]  A. Nizam,et al.  Containing Pandemic Influenza at the Source , 2005, Science.

[39]  Frederick Hayden,et al.  Developing new antiviral agents for influenza treatment: what does the future hold? , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  Oseltamivir-Resistant Influenza A Viruses Circulating in Japan , 2009, Journal of Clinical Microbiology.

[41]  A. Lackenby,et al.  Oseltamivir-Resistant Influenza Viruses A (H1N1), Norway, 2007–08 , 2009, Emerging infectious diseases.

[42]  M. Zambon,et al.  Influenza antiviral susceptibility monitoring activities in relation to national antiviral stockpiles in Europe during the winter 2006/2007 season. , 2007, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[43]  M. Halloran,et al.  Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. , 2006, American journal of epidemiology.

[44]  T. Finsterbusch,et al.  Low Dose Oral Combination Chemoprophylaxis with Oseltamivir and Amantadine for Influenza a Virus Infections in Mice , 2007, Journal of chemotherapy.

[45]  I. Longini,et al.  What is the best control strategy for multiple infectious disease outbreaks? , 2007, Proceedings of the Royal Society B: Biological Sciences.

[46]  W. Edmunds,et al.  Delaying the International Spread of Pandemic Influenza , 2006, PLoS medicine.